ADC BIO Secures $11 Million Facilities Investment.
Customer demand for ‘Lock-Release’ aggregation control technology a key driver behind expansion into clinical & commercial drug manufacturing.
ADC BIO has secured investment for the construction of an $11 million bio-conjugation facility at its new site in Deeside, North Wales, UK.
The 6,500m2 facility – scheduled to be operational by September 2018 – will support manufacturing in all clinical phases and small-scale commercial production of antibody drug conjugates. It will provide GMP production suites equipped with vessels of 10 up to a few hundred litres for batch sizes from 100 grams up to a kilo. The new integrated facility will enable ADC Bio to complement its long established technical services business that provides small scale R&D through to pre-clinical testing, with three on site laboratories and analytical testing capabilities.